PER 0.00% 10.0¢ percheron therapeutics limited

News: ANP Antisense Therapeutics says ATL1102 for MS Phase IIb IND submitted to FDA for review, page-36

  1. 11,041 Posts.
    lightbulb Created with Sketch. 985
    Wow, wouldn't that be something.
    I think that would be a great gesture if Mark Diamond did that.
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.